TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC)....
NEWARK, Del. and NANJING, China, Jan. 8, 2024 /PRNewswire/ -- The Partner of Biosion Inc. (Biosion) , OBI Pharma (4174.TWO), announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for OBI-992, to conduct a Phase 1/2 study of its novel antibody drug conjugate (ADC) cancer therapy targeting TROP2. The targeting antibody was discovered through Biosion's SynTracer® High Throughput Endocytosis Platform and was licensed to OBI Pharma in Dec 2021. OBI Pharma owns ex-China commercial rights for OBI-992 (BSI-992), and Biosion owns China rights.
TAIPEI, Taiwan, Jan. 03, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, a clinical stage oncology company (4174.TWO), today announced that the U.S. Food and Drug Administration (FDA) has cleared an...
Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally. She brings a wealth...
TAIPEI, Taiwan, April 10, 2023 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab (anti-PD1 mAb) in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell (CAR T) immunotherapy targeting Globo H. These data will be presented at the American Association of Cancer Research (AACR) Annual Meeting from 14th-19th April, 2023 in Orlando, Florida (USA). nnOBI’s Chief Scientific Officer Ming-Tain Lai, Ph.D., commented that “Our scientific data suggest OBI-999 creates a tumor microenvironment that can significantly enhance the function of pembrolizumab. This potentiated anti-tumor effect was evident in four different xenograft models (breast, gastric, colorectal, and small cell lung cancer) that expressed Globo H and PD-1. These findings support the clinical study of combination therapeutic strategies that pair OBI-999 with anti PD-1/PD-L1 cancer therapeutics. OBI has also developed the first CAR T-cell therapy (OBI-R007) targeting Globo H, which demonstrates a strong and specific anti-tumor effect on Globo H-expressing tumor cells. These encouraging results warrant further development of this novel cellular therapy.” nnTitle: OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab nAuthors1: Chun-Chung Wang, Chi-Huan Lu, Jhih-Jie Yang, Wan-Fen Li, Ming-Tain Lai. nnSession Title: Tumor-Stromal Cell (Including Immune Cell) Interactions and Therapy Responses nLocation: Section 7 nPoster Board Number: 5946/7 nAbstract Presentation Number: 5946 nSession Date and Time: Wednesday Apr 19, 2023, 9:00 AM - 12:30 PM nnTitle: Globo H-targeted CAR T cell cancer immunotherapy nAuthors1: Jiann-Shiun Lai, Shiou-Ling Jian, Woan-Eng Chan, Ming-Tain
TAIPEI, Taiwan, July 05, 2022 (GLOBE NEWSWIRE) -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced discontinuation of the Phase 1/2 Study* for OBI 888, a Globo H antibody, upon...
TAIPEI, Taiwan, May 17, 2022 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174), a leader in First-in-Class Cancer therapeutics, today announced that data highlighting ongoing clinical studies...
TAIPEI, Taiwan, April 7, 2022 /PRNewswire/ -- OBI Pharma, Inc. (TPEx: 4174) today announced scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab (PD-1) and the association of high Globo H and PD-L1 expression resulting in poor survival in gastric cancer patients, will be presented at the American Association of Cancer Research (AACR) Annual Meeting from April 8–13, 2022 in New Orleans, LA. (USA).
TAIPEI, Taiwan, April 26, 2021 /PRNewswire/ -- OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S.-based SWOG Cancer Research Network has started patient enrollment for a Phase I/II study of OBI-3424, a first-in-class (small-molecule prodrug) DNA alkylating agent that targets cancers expressing the aldo-keto reductase 1C3 (AKR1C3) enzyme.